Oxidative Stress-induced MiR-27a Targets the Redox Gene Nuclear Factor Erythroid 2-related Factor 2 in Diabetic Embryopathy
Overview
Affiliations
Background: Maternal diabetes induces neural tube defects, and oxidative stress is a causal factor for maternal diabetes-induced neural tube defects. The redox gene nuclear factor erythroid 2-related factor 2 is the master regulator of the cellular antioxidant system.
Objective: In this study, we aimed to determine whether maternal diabetes inhibits nuclear factor erythroid 2-related factor 2 expression and nuclear factor erythroid 2-related factor 2-controlled antioxidant genes through the redox-sensitive miR-27a.
Study Design: We used a well-established type 1 diabetic embryopathy mouse model induced by streptozotocin for our in vivo studies. Embryos at embryonic day 8.5 were harvested for analysis of nuclear factor erythroid 2-related factor 2, nuclear factor erythroid 2-related factor 2-controlled antioxidant genes, and miR-27a expression. To determine if mitigating oxidative stress inhibits the increase of miR-27a and the decrease of nuclear factor erythroid 2-related factor 2 expression, we induced diabetic embryopathy in superoxide dismutase 2 (mitochondrial-associated antioxidant gene)-overexpressing mice. This model exhibits reduced mitochondria reactive oxygen species even in the presence of hyperglycemia. To investigate the causal relationship between miR-27a and nuclear factor erythroid 2-related factor 2 in vitro, we examined C17.2 neural stem cells under normal and high-glucose conditions.
Results: We observed that the messenger RNA and protein levels of nuclear factor erythroid 2-related factor 2 were significantly decreased in embryos on embryonic day 8.5 from diabetic dams compared to those from nondiabetic dams. High-glucose also significantly decreased nuclear factor erythroid 2-related factor 2 expression in a dose- and time-dependent manner in cultured neural stem cells. Our data revealed that miR-27a was up-regulated in embryos on embryonic day 8.5 exposed to diabetes, and that high glucose increased miR-27a levels in a dose- and time-dependent manner in cultured neural stem cells. In addition, we found that a miR-27a inhibitor abrogated the inhibitory effect of high glucose on nuclear factor erythroid 2-related factor 2 expression, and a miR-27a mimic suppressed nuclear factor erythroid 2-related factor 2 expression in cultured neural stem cells. Furthermore, our data indicated that the nuclear factor erythroid 2-related factor 2-controlled antioxidant enzymes glutamate-cysteine ligase catalytic subunit, glutamate-cysteine ligase modifier subunit, and glutathione S-transferase A1 were down-regulated by maternal diabetes in embryos on embryonic day 8.5 and high glucose in cultured neural stem cells. Inhibiting miR-27a restored expression of glutamate-cysteine ligase catalytic subunit, glutamate-cysteine ligase modifier subunit, and glutathione S-transferase A1. Overexpressing superoxide dismutase 2 reversed the maternal diabetes-induced increase of miR-27a and suppression of nuclear factor erythroid 2-related factor 2 and nuclear factor erythroid 2-related factor 2-controlled antioxidant enzymes.
Conclusion: Our study demonstrates that maternal diabetes-induced oxidative stress increases miR-27a, which, in turn, suppresses nuclear factor erythroid 2-related factor 2 and its responsive antioxidant enzymes, resulting in diabetic embryopathy.
Association between genetic variants in hsa-miR-27a and hsa-miR-146a genes and male infertility.
Rajovski S, Matijasevic-Jokovic S, Milanovic N, Radovanovic N, Brkusanin M, Savic-Pavicevic D J Med Biochem. 2025; 43(6):936-945.
PMID: 39876905 PMC: 11771969. DOI: 10.5937/jomb0-50876.
The Role of NRF2 in Trinucleotide Repeat Expansion Disorders.
Chang K, Chen C Antioxidants (Basel). 2024; 13(6).
PMID: 38929088 PMC: 11200942. DOI: 10.3390/antiox13060649.
Hong J, Tong H, Wang X, Lv X, He L, Yang X Front Endocrinol (Lausanne). 2024; 14:1135837.
PMID: 38170036 PMC: 10759208. DOI: 10.3389/fendo.2023.1135837.
The untapped potential of targeting NRF2 in neurodegenerative disease.
Chen W, Dodson M Front Aging. 2023; 4:1270838.
PMID: 37840813 PMC: 10569223. DOI: 10.3389/fragi.2023.1270838.
Silva-Llanes I, Shin C, Jimenez-Villegas J, Gorospe M, Lastres-Becker I Antioxidants (Basel). 2023; 12(3).
PMID: 36978889 PMC: 10045347. DOI: 10.3390/antiox12030641.